NT 0796
Alternative Names: NT-0796Latest Information Update: 05 Jun 2024
At a glance
- Originator Ryvu Therapeutics
- Developer Nodthera
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Inflammasome inhibitors; NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Inflammation
Most Recent Events
- 15 Apr 2024 NodThera Limited completes phase I/II clinical trials in Inflammation in USA (PO) (NCT06129409)
- 10 Oct 2023 Phase-I/II clinical trials in Inflammation in USA (PO) (NCT06129409)
- 26 Sep 2022 NodThera completes a phase I trial in Inflammation (In volunteers) in New Zealand (PO) (ACTRN12621001082897)